Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Working Capital Changes (2016 - 2025)

Cytokinetics (CYTK) has disclosed Other Working Capital Changes for 16 consecutive years, with -$9.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes changed N/A to -$9.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$17.1 million, a N/A change, with the full-year FY2025 number at -$10.8 million, down 49.63% from a year prior.
  • Other Working Capital Changes was -$9.2 million for Q4 2025 at Cytokinetics, down from $376000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $29.8 million in Q3 2021 to a low of -$95.0 million in Q3 2022.
  • A 5-year average of -$3.5 million and a median of $308000.0 in 2024 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: tumbled 418.82% in 2022, then surged 5625.0% in 2024.
  • Cytokinetics' Other Working Capital Changes stood at $10.0 million in 2021, then plummeted by 1049.76% to -$95.0 million in 2022, then soared by 98.81% to -$1.1 million in 2023, then surged by 121.16% to $240000.0 in 2024, then plummeted by 3952.5% to -$9.2 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Other Working Capital Changes are -$9.2 million (Q4 2025), $376000.0 (Q1 2025), and $240000.0 (Q3 2024).